Background: Decreased availability of the N-methyl-D-aspartate receptor (NMDAR) co-agonist D-serine is thought to promote NMDAR hypofunction and contribute to the pathophysiology of schizophrenia, including neuroanatomical abnormalities, such as cortical atrophy and ventricular enlargement, and neurochemical abnormalities, such as aberrant glutamate and γ-aminobutyric acid (GABA) signaling. It is thought that these abnormalities directly relate to the negative symptoms and cognitive impairments that are hallmarks of the disorder. Because of the genetic complexity of schizophrenia, animal models of the disorder are extremely valuable for the study of genetically predisposing factors. Our laboratory developed a transgenic mouse model lacking serine racemase (SR), the synthetic enzyme of D-serine, polymorphisms of which are associated with schizophrenia. Null mutants (SR
Introduction
Schizophrenia is a devastating psychiatric disorder that affects 1% of the population worldwide (Perälä et al., 2007) . The disease manifests in several different endophenotypes through a combination of heterogeneous symptom domains including positive symptoms (e.g., hallucinations, delusions, and thought disorder), negative symptoms (e.g., blunted affect and poverty of speech), and cognitive impairments (e.g., deficits in working memory and attention). Most current therapies do little to treat the negative symptoms and cognitive impairments, which are often reported as the most disabling by individuals with schizophrenia (Coyle, 2006) .
A prominent hypothesis proposes that activity of the N-methyl-D-aspartate receptor (NMDAR) is decreased in individuals with schizophrenia relative to healthy controls (Coyle, 2006; Coyle et al., 2002; Javitt, 2007; Javitt and Zukin, 1991) . NMDAR hypofunction may be due, in part, to decreased availability of D-serine, an NMDAR co-agonist, given that genes encoding serine racemase (SR; the synthetic enzyme for D-serine), D-amino acid oxidase (DAAO; the degradation enzyme for D-serine), and the DAAO activator G72 are risk genes for schizophrenia (Petryshen et al., 2005; Ripke et al., 2014; Williams et al., 2004; Wroblewska et al., 1997) and that expression of SR (Steffek et al., 2006; Verrall et al., 2007) and DAAO (Habl et al., 2009; Madeira et al., 2008) is altered in individuals with schizophrenia. Evidence suggests that one of the consequences of NMDAR hypofunction is downregulation of fast-firing, parvalbumin-positive γ-aminobutyric acid (GABA) interneurons, resulting in disinhibition of pyramidal neurons (Benes and Berretta, 2001; Lewis and Hashimoto, 2007) and a hyperglutamatergic state (Lisman et al., 2008; Moghaddam et al., 1997) . Indeed, unmedicated (i.e., antipsychotic naïve or off antipsychotic medications for at least 2 weeks) humans with schizophrenia exhibit increases in glutamate levels (Kegeles et al., 2012; de la Fuente-Sandoval et al., 2011 , 2013 , as well as increases in GABA levels (Kegeles et al., 2012; Neurobiology of Disease 73 (2015) 269-274 
